BioPharma Services (BPSI) has entered into a partnership and joint venture agreement with Scentryphar, a CRO located in Sao Paulo, Brazil. The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one-stop shopping and joint experience in clinical conduct, bioanalysis, data management, statistics and scientific and medical writing.

BioPharma Services is a physician-owned, physician-run, FDA-inspected, U.K. MHRA-inspected and Health Canada-inspected international CRO. It is privately held and is headquartered in Toronto.

“We are extremely pleased to partner with Scentryphar to offer generic and phases I-IV project management for Brazilian submission. This strategic alliance will allow our sponsors to bring products in Brazil in a timely fashion while maintaining high quality standards,” said Renzo DiCarlo, CEO at BPSI.